JANX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Janux Therapeutics Inc

NASDAQ | JANX

26.48

USD

$0.00

(

0.00%

)

At Close (As of Nov 7, 2025)

$1.72B

Market Cap

-

P/E Ratio

-1.81

EPS

$71.70

52 Week High

$21.73

52 Week Low

HEALTHCARE

Sector

JANX Chart

Recent Chart
Price Action

JANX Technicals

Tags:

JANX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $8.5M
Total Revenue $11M
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$99M
Selling General And Administrative $41M
Research And Development $68M
Operating Expenses $107M
Investment Income Net -
Net Interest Income $30M
Interest Income $30M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$69M

Revenue & Profitability

Earnings Performance

JANX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.1B
Total Current Assets $1B
Cash And Cash Equivalents At Carrying Value $431M
Cash And Short Term Investments $431M
Inventory -
Current Net Receivables $5.4M
Total Non Current Assets $28M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $595M
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $17M
Current Accounts Payable $4M
Deferred Revenue -
Current Debt -
Short Term Debt $3.5M
Total Non Current Liabilities $21M
Capital Lease Obligations $23M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $23M
Other Current Liabilities $9.9M
Other Non Current Liabilities -
Total Shareholder Equity $1B
Treasury Stock -
Retained Earnings -$238M
Common Stock $59K
Common Stock Shares Outstanding $54M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$44M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.1M
Capital Expenditures $359K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$258M
Cashflow From Financing $713M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$69M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $8.5M
Total Revenue $11M
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$99M
Selling General And Administrative $41M
Research And Development $68M
Operating Expenses $107M
Investment Income Net -
Net Interest Income $30M
Interest Income $30M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$69M

JANX News

JANX Profile

Janux Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Janux Therapeutics, Inc. is an innovative biopharmaceutical company based in La Jolla, California, specializing in the development of advanced immunotherapies for cancer treatment through its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company aims to enhance patient outcomes by creating therapies that specifically target and eliminate tumor cells, addressing critical unmet needs in oncology. With a strong emphasis on T cell biology and tumor activation mechanisms, Janux is poised to make significant contributions to cancer care, driven by its cutting-edge research and strategic focus on innovative therapeutic solutions.

BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
ONDS
+10.66%
$5.81
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
WTO
-7.52%
$0.04
BITF
-0.81%
$3.66
SNAP
+2.49%
$8.21
AAL
+3.80%
$13.65
AXDX
-61.36%
$0.03
NIO
-4.18%
$6.86
RIVN
+0.06%
$15.23
CHR
+0.15%
$0.06
DVLT
+24.26%
$1.69
T
+0.36%
$24.83
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BURU
+3.54%
$0.28
BTG
+2.89%
$3.91
PBR
+5.93%
$12.86
IREN
-6.83%
$62.38
JOBY
+4.05%
$14.90
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
YDKG
-1.56%
$0.05
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
CIFR
-4.69%
$20.69
HOOD
+2.58%
$130.36
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
SMR
-6.53%
$30.34
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
NOK
-1.01%
$6.84
BAC
-0.16%
$53.20
RMBL
+60.50%
$3.21
ABEV
+1.25%
$2.43
RIG
+2.05%
$3.98
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
VIVK
+11.85%
$0.16
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
GOOGL
-2.07%
$278.83
TTD
-6.31%
$43.00
CMG
+0.09%
$30.59
QS
+4.52%
$16.62
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
IONQ
+3.20%
$59.27
PLTZ
-3.51%
$6.86
FIG
-3.76%
$44.25
EPWK
+3.23%
$0.07
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.30%
$2.41
RF
+2.22%
$24.85
META
+0.44%
$621.71
MTC
-6.85%
$2.58
PTON
+14.15%
$7.66
ELDN
-49.75%
$2.06
IOVA
-0.43%
$2.29
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
CAN
+5.30%
$1.19
VZ
+0.52%
$40.03
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36
BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
ONDS
+10.66%
$5.81
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
WTO
-7.52%
$0.04
BITF
-0.81%
$3.66
SNAP
+2.49%
$8.21
AAL
+3.80%
$13.65
AXDX
-61.36%
$0.03
NIO
-4.18%
$6.86
RIVN
+0.06%
$15.23
CHR
+0.15%
$0.06
DVLT
+24.26%
$1.69
T
+0.36%
$24.83
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BURU
+3.54%
$0.28
BTG
+2.89%
$3.91
PBR
+5.93%
$12.86
IREN
-6.83%
$62.38
JOBY
+4.05%
$14.90
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
YDKG
-1.56%
$0.05
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
CIFR
-4.69%
$20.69
HOOD
+2.58%
$130.36
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
SMR
-6.53%
$30.34
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
NOK
-1.01%
$6.84
BAC
-0.16%
$53.20
RMBL
+60.50%
$3.21
ABEV
+1.25%
$2.43
RIG
+2.05%
$3.98
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
VIVK
+11.85%
$0.16
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
GOOGL
-2.07%
$278.83
TTD
-6.31%
$43.00
CMG
+0.09%
$30.59
QS
+4.52%
$16.62
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
IONQ
+3.20%
$59.27
PLTZ
-3.51%
$6.86
FIG
-3.76%
$44.25
EPWK
+3.23%
$0.07
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.30%
$2.41
RF
+2.22%
$24.85
META
+0.44%
$621.71
MTC
-6.85%
$2.58
PTON
+14.15%
$7.66
ELDN
-49.75%
$2.06
IOVA
-0.43%
$2.29
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
CAN
+5.30%
$1.19
VZ
+0.52%
$40.03
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.